stars 1 stars 2 stars 3

Olpha, the subsidiary of JSC AB City, is one of the largest companies in the Baltic states with more than 50 years of experience in the production of medicines and chemical pharmaceutical products. Portfolio contains over 60 FDFs, 25 APIs and more than 25 Intermediates. The key areas of specialization in FDFs include neurology, cardiology, infectology and allergology. Olainfarm has a long-standing technological and know-how advantage in adamantane, quinuclidine and nitrofurane chemistry. Olpha Group includes a network of medical and pharmaceutical enterprises specialising in their own discipline, covering a wide range of areas - supplement manufacturers Silvanols, RFF and Jonax. Olainfarm is certified in accordance with the requirements of the EU GMP for APIs and FDFs, the U.S. cGMP for certain APIs (FDA), TGA for FDFs (Australia), CEP for certain APIs, ISO 14001 Environmental Management System and ISO 17025 Laboratory Management System. Visit http://www.olpha.eu/ for more information. Current vacancies: https://olpha.eu/en/careers

Olpha Global Questions

The Olpha Global annual revenue was $6.3 million in 2026.

Inga Liscika is the CFO of Olpha Global.

219 people are employed at Olpha Global.

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users